Abilify Asimtufii Injection, Suspension, Extended Release
NDC Package 59148-102-80
Package Information
Abilify Asimtufii (aripiprazole) injection is aripiprazole is used to treat certain mental/mood disorders (such as bipolar disorder, schizophrenia, Tourette's syndrome, and irritability associated with autistic disorder). This formulation utilizes a injection, suspension, extended release delivery system. Marketed by Otsuka America Pharmaceutical, Inc, this product is identified by NDC 59148-102 and is authorized under FDA application NDA217006.
Identification & Billing
- RxCUI: 2636637 - ARIPiprazole 720 MG in 2.4 ML Extended Release Prefilled Syringe
- RxCUI: 2636637 - 2.4 ML aripiprazole 300 MG/ML Prefilled Syringe
- RxCUI: 2636637 - aripiprazole 720 MG per 2.4 ML extended release Prefilled Syringe
- RxCUI: 2636640 - Abilify Asimtufii 720 MG in 2.4 ML Extended Release Prefilled Syringe
- RxCUI: 2636640 - 2.4 ML aripiprazole 300 MG/ML Prefilled Syringe [Abilify]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59148 - Otsuka America Pharmaceutical, Inc
- 59148-102 - Abilify Asimtufii
- 59148-102-80 - 1 SYRINGE in 1 CARTON / 2.4 mL in 1 SYRINGE
- 59148-102 - Abilify Asimtufii
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59148-102-80 identifies a specific commercial package of 1 syringe in 1 carton / 2.4 ml in 1 syringe of Abilify Asimtufii, a human prescription drug labeled by Otsuka America Pharmaceutical, Inc. This injection, suspension, extended release is formulated for intramuscular use and contains aripiprazole as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Otsuka America Pharmaceutical, Inc on April 27, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Aripiprazole is used to treat certain mental/mood disorders (such as bipolar disorder, schizophrenia, Tourette's syndrome, and irritability associated with autistic disorder). It may also be used in combination with other medication to treat depression. Aripiprazole is known as an antipsychotic drug (atypical type). It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters). This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. Aripiprazole can treat severe mood swings and decrease how often mood swings occur.
How is this Otsuka America Pharmaceutical, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59148010280. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.